Company Profile

Eargo, Inc. is a medical device company. The Company is engaged in developing products to improve the quality of life of people with hearing loss. Its Eargo hearing aids are virtually invisible, rechargeable, completely in-the-canal devices indicated to compensate for mild to moderate hearing loss. Its in-the-canal devices feature quality audio, which are designed to provide up to 16 hours of battery life and feature its soft flexible medical-grade silicon tips. It is marketing various versions of hearing aids, the Eargo Max, the Eargo Neo HiFi, Eargo 5, Eargo 6 and Eargo 7. The Company markets and sells its hearing aids primarily in a direct-to-consumer format, engaging consumers through a mix of digital and traditional marketing as well as select commercial partnership, and omni-channel (including retail). Its devices are self-fitting hearing aids and are adjusted by the user to meet the user's hearing needs, without pre-programming or a hearing test from a hearing care professional.

Employees

243

Sector

Advanced Medical Equipment & Technology

More about the company

25-05-13	Eargo Launches Eargo 8 as Its Newest Hearing Aid	CI
25-03-31	Eargo and hearX Group Appoints Nic Klopper as CEO for LXE Hearing	CI
25-03-31	Eargo and hearX Group Appoints Bill Brownie as COO for LXE Hearing	CI
24-02-20	Eargo, Inc.(NasdaqGS:EAR) dropped from S&P TMI Index	CI
24-02-18	Eargo, Inc.(NasdaqGS:EAR) dropped from NASDAQ Composite Index	CI
24-01-31	Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings	CI
24-01-05	Twist Bioscience Names Adam Laponis Chief Financial Officer	MT
23-12-22	Eargo, Inc. Announces Chief Financial Officer Changes, Effective from January 5, 2024	CI
23-11-07	Eargo, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-10-30	Top Midday Gainers	MT
23-10-30	Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	MT
23-10-29	Patient Square Capital, LP entered into an agreement to acquire remaining 23.8% stake in Eargo, Inc. for $13 million.	CI
23-10-26	Eargo Expands Relationship with Best Buy, Growing In-Store Presence to over 500 Locations	CI

22-08-09	Wells Fargo Adjusts Eargo Price Target to $2 From $10, Maintains Equal Weight Rating	MT
21-09-24	Analyst recommendations: Boohoo, Coca-Cola, Monster Beverage, Molson Coors, Philip Morris...
21-09-23	EARGO : William Blair Downgrades Eargo to Market Perform Rating From Outperform	MT
21-09-23	EARGO : JPMorgan Downgrades Eargo to Underweight From Overweight, Price Target at $11	MT
21-09-23	EARGO : Wells Fargo Downgrades Eargo to Equalweight From Overweight, Price Target at $10	MT

24-05-09	Eargo : Clinically Standard Verification and Validation of OTC Self-Fitting Hearing Aids	PU
24-01-31	Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings	AQ
24-01-17	Northern District Of California Grants Motion To Dismiss Amended Securities Class Action Complaint Against Hearing Aid Company	AQ
24-01-16	EARGO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Eargo, Inc. - EAR	BU
24-01-08	Twist Bioscience Appoints Adam Laponis as Chief Financial Officer	AQ

Manager	Title	Age	Since
William Brownie CEO	Chief Executive Officer	59	2023-06-29
Mark Thorpe DFI	Director of Finance/CFO	58	2024-01-04
Fred Knight CMP	Compliance Officer	-	2022-07-31

Director	Title	Age	Since
Donald Spence CHM	Chairman	72	2022-12-06
David Wu BRD	Director/Board Member	57	2014-06-30
Justin Sabet-Peyman BRD	Director/Board Member	43	2022-12-06

Eargo, Inc. Stock

Stocks

EAR

US2700872086

Advanced Medical Equipment & Technology

Latest news : Eargo, Inc.

Analysts' recommendations: Eargo, Inc.

Press Releases: Eargo, Inc.

News in other languages: Eargo, Inc.

Quotes and Performance

Managers and Directors: Eargo, Inc.

Latest insider transactions

Other Advanced Medical Equipment & Technology

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/16/24	Trit Garg	Issuer sale	Director	10,859	0.0523%
2/16/24	Justin Sabet-Peyman	Issuer sale	Director	10,859	0.0523%
2/16/24	Donald Spence	Issuer sale	Chairman	10,859	0.0523%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EARGO, INC.	-4.10%	-2.28%	-	-	53.39M
THERMO FISHER SCIENTIFIC, INC.	+1.48%	+3.52%	+30.48%	+2.61%	202B
DANAHER CORPORATION	+2.10%	+4.61%	+6.06%	-14.77%	145B
INTUITIVE SURGICAL, INC.	+3.43%	-2.24%	-21.52%	+13.65%	142B
BOSTON SCIENTIFIC CORPORATION	+3.67%	-0.82%	-56.76%	-15.86%	66.32B
EDWARDS LIFESCIENCES CORPORATION	+0.65%	-3.82%	+15.37%	-5.93%	50.58B
SIEMENS HEALTHINEERS AG	+0.27%	+1.94%	-24.32%	-31.53%	44.81B
AGILENT TECHNOLOGIES, INC.	+1.03%	+1.88%	+19.99%	+13.65%	38.44B
WATERS CORPORATION	+0.87%	+0.28%	+30.61%	+39.67%	37.13B
GE HEALTHCARE TECHNOLOGIES INC.	+3.96%	+1.55%	-12.92%	-19.70%	29.89B
Average	-0.26%	+1.13%	-1.45%	-2.02%	84.07B
Weighted average by Cap.	-0.76%	+1.83%	+1.86%	-1.36%